 Home > Active Ingredient News > Drugs Articles > Personnel changes in March. The executives of multinational pharmaceutical companies/local pharmaceutical companies exchanged, involving Baiji, Pfizer, Junshi...

Personnel changes in March. The executives of multinational pharmaceutical companies/local pharmaceutical companies exchanged, involving Baiji, Pfizer, Junshi...

 Last Update: 2022-04-27
 Source: Internet
 Author: User

Tags

sulfa based drugs

team leader job description

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

March in the world coincides with the golden three silver four job hunting season
.

Looking at the announcements of major pharmaceutical companies, high-level personnel changes were particularly frequent in March

According to incomplete statistics, a total of 28 executives resigned in March, and 39 executives took up new positions, involving not only multinational pharmaceutical companies such as AstraZeneca, Pfizer, and Eli Lilly, but also Junshi Bio, BeiGene, Shanghai Pharmaceuticals, etc.
Among the local star pharmaceutical companies, there are many executives such as chairman and CEO
.

It is worth mentioning that in March, the phenomenon of "executive exchanges" between multinational pharmaceutical companies and local pharmaceutical companies was obvious
.

For example, the former CFO of Eli Lilly joined a local innovative pharmaceutical company, Junshi Chu Nan joined Pfizer, and the former BeiGene Hematology Chief Medical Officer joined Prelude.

In addition, the chairman of Hainan Haiyao "changes every year", and the wife of Fangsheng Pharmaceutical's resignation is "up".
.
.
What are the "rare things" behind the flow of personnel?

1.
Resignation and Inauguration of the Chairman

In terms of resignation, most of the reasons are personal, followed by other reasons such as "looking for external opportunities for job adjustment"
.

This month involves the resignation of 3 chairman, namely:

Zhang Qinghua, Chairman of Fangsheng Pharmaceutical

Liu Shaoyun, Chairman of Heavy Pharmaceutical Holdings

Pan Dazhong, Chairman of Hainan Haiyao

Among them, Zhang Qinghua and Liu Shaoyun resigned due to personal reasons, while Pan Dazhong resigned as chairman when he reached the retirement age
.

>>>> The chairman of Fangsheng Pharmaceutical is a "husband and wife file" before and after the coaching change

On March 4, 2022, Fangsheng Pharmaceutical announced that the board of directors received a written resignation report submitted by Zhang Qinghua, chairman and general manager of the company.
Director, director of the strategic development committee of the board of directors and general manager
.

Since then (March 6), Fangsheng Pharmaceutical announced the election of Zhou Xiaoli as the chairman of the fifth board of directors and director of the strategic development committee of the company, and appointed Zhou Xiaoli as the general manager of the company, and the term of office will end when the current board of directors expires
.

It is worth mentioning that according to public information, Zhang Qinghua and Zhou Xiaoli are married
.

>>>> Hainan Haiyao chairman "changes every year"?

On March 29, 2022, Hainan Haiyao announced that Pan Dazhong applied for his resignation as the company's director, chairman, convener of the strategy committee of the board of directors and member of the nomination committee due to retirement reasons
.

After resigning, Pan Dazhong will not hold any position in the company

It is worth noting that Pan Dazhong officially took over as chairman of Hainan Haiyao for just over a year
.

Previously (January 29, 2021), Hainan Haiyao announced that Cheng Aimin had applied to resign as the company's chairman, director, convener of the strategy committee of the board of directors and member of the nomination committee due to work adjustment
.

At the same time, the board of directors elected Pan Dazhong as the chairman of the tenth board of directors of the company

Cheng Aimin took office for less than a year.
After being formally acquired by state-owned assets in 2020, he succeeded Liu Xicheng as the chairman of Hainan Haiyao
.

>>>> Liu Shaoyun, Chairman of Heavy Pharmaceutical Holdings, resigns

On March 11, Heavy Pharmaceutical Holdings announced that Liu Shaoyun had applied for his resignation as chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors due to personal reasons
.

After Liu Shaoyun resigned from the above-mentioned positions, he took up a first-level professional position in Heavy Pharmaceutical Holdings

Yuan Quan, its director and general manager, was jointly elected by all the current directors of Sinopharm Holding to perform the duties of the chairman and act as its legal representative at the same time
.

On the same day, Zhang Hong of Heavy Pharmaceutical Holdings applied for his resignation as deputy general manager and chief financial officer because he had reached the legal retirement age
.

After Zhang Hong resigns, she will no longer hold other positions

2.
"Executive exchanges" between multinational and local pharmaceutical companies have become the norm

In recent years, the flow of personnel between multinational pharmaceutical companies and local innovative pharmaceutical companies has become increasingly frequent and has become the norm
.

In March, many multinational pharmaceutical companies and local pharmaceutical companies "interacted" again and again

>>>> Huang Weijuan: Chief Medical Officer of BeiGene Hematology → President and Chief Medical Officer of Prelude

On March 4, 2022, BeiGene announced that Dr.
Jane Huang (Huang Weijuan), the company's senior management and core technician, will officially resign as the company's chief medical officer of hematology on April 3, 2022 due to personal planning
.

On March 9, Prelude Therapeutics announced that it had hired Dr.
Huang as President and Chief Medical Officer, effective April 4
.

Prelude Therapeutics is a clinical-stage biopharmaceutical company developing innovative medicines targeting key cancer cell pathways

>>>> Chu Nan: Vice President of Marketing and Medical Affairs of Junshi Biological → Pfizer Digestive/Urinary/Hematologic Oncology Area Leader

Recently, Pfizer appointed Chu Nan as the head of the digestive system/urology/hematological oncology field of the Oncology Business Unit, and reported directly to Wang Yiqin, the General Manager of the Oncology Business Unit.
The appointment will take effect on March 28, 2022
.

It is reported that Chu Nan will be responsible for managing the sales and marketing teams of Pfizer China in the field of digestive system/urinary/hematological oncology, formulate effective product and market strategies, develop and promote the business development of product pipelines with strategic thinking, and make better use of products.
potential to drive rapid business growth
.

Before joining Pfizer, Chu Nan served as Vice President of Marketing and Medical Affairs at Shanghai Junshi Biosciences, responsible for the oncology product portfolio strategy and the internationalization strategy of innovative drugs
.

>>>> Josh Smiley: Eli Lilly CFO → Chief Operating Officer of Zai Lab

On March 15, Zai Lab announced the appointment of Josh Smiley as chief operating officer, with overall management of all aspects of business, finance and global operations
.
The official inauguration date is August 1, 2022
.

Previously, Smiley was responsible for finance, corporate strategy, business development, venture capital and global business services operations at Eli Lilly, most recently as senior vice president and chief financial officer
.

>>>> Dr.
Danny Chen: Senior Vice President of SciNeuro → Senior Vice President of Simcere Pharma

On March 28, Simcere announced the appointment of Dr.
Danny Chen as the Group Senior Vice President, responsible for promoting the company's translational science and neurological research and development work, as well as the establishment and management of the Beijing Innovation Center's research and development team to enhance Simcere's central nervous system therapeutics.
global R&D capabilities
.

Dr.
Danny Chen joined Simcere as Senior Vice President of SciNeuro, responsible for non-clinical development and translational medicine
.
Before that, he worked for Pfizer (US) Neuroscience R&D department for many years and served as the head of the department, and he was the chief scientist at Purdue Pharma in the early days
.

>>>> Wu Kun: Former COO of Pfizer China → Chief Commercial Officer of Jixing Pharmaceutical

On March 31, Keixing Pharmaceutical announced the appointment of Wu Kun as Chief Commercial Officer, responsible for formulating Keixing's commercialization strategy and establishing an excellent marketing team to drive the commercialization of the company's growing product portfolio
.
Wu Kun will be based in Shanghai, China, reporting to Luo Wanli, CEO of Keixing
.

Before joining Jixing, Wu Kun served as Chief Operating Officer of China at Pfizer, leading a 5,000-person team consisting of sales, marketing, key accounts, commercial and business operations functions
.

>>>> Xia Shaofei: Former Head of Novartis Oncology (China) Hematology Business Unit → CEO of Hessen Biopharmaceuticals

In early March, Novartis Oncology announced a personnel change, and Xia Shaofei, head of its blood division, will leave Novartis to seek external career opportunities
.
This position will also be temporarily represented by Wang Wei, the current head of the North First District of Novartis Oncology
.

On March 16, Hessen Biopharmaceutical announced that with the approval of the board of directors, Summer Xia will join Hessen Biomedical as Chief Executive Officer (CEO)
.

>>>> Fan Jie: Senior management of Xi'an Janssen → CEO of Mace Medical

On March 1, Mays Medical officially announced that Fan Jie was appointed as the CEO and officially joined Mays Medical to fully participate in strategy formulation and business management
.

Before joining Mays Medical, Fan Jie served as a senior executive of Janssen in Xi'an and the general manager of Actelon Pharmaceuticals.
In his early years, he also served well-known multinational pharmaceutical companies such as Schering-Plough
.

>>>> Lian Jia: President of Cardional Health China and Asia Pacific → CEO of Pamu Medical

On March 10, Pamu Medical announced that it has appointed Jessie Lian as the company's chief executive officer.
At the same time, she will join Pamu Medical's board of directors and will be fully responsible for the company's business and operational management
.

Before joining Palmer Medical, Lian Jia worked at Johnson & Johnson.
Starting from the front-line business, he has served as the director of several business units, and managed the operations and support departments horizontally.
Later, he joined Cardional Health as the general manager of China.
, Vice President of Asia Pacific Strategic Marketing Department; President of China and Asia Pacific after the Cordis business became independent
.

In addition, after Zhao Ping, the former general manager of Greater China of CStone Pharmaceuticals, left, Zhou You, the former chief marketing officer of Sanofi China, joined as its general manager of Greater China
.

>>>> Zhao Ping: General Manager of CStone Greater China → CEO of Binuoji

On March 28, Binuoji announced that co-founder Zhao Ping officially became the chief executive officer (CEO) of the company, and will be fully responsible for the development strategy, pipeline and operation management of Binuoji, and lead Binuoji to rapidly grow into a global leader.
cell therapy innovator
.

Before joining Binuoji, Ms.
Zhao Ping served as General Manager of China for Genzyme, Allergen, Bristol-Myers Squibb (BMS) and CStone
.

>>>> Travel: Former Chief Marketing Officer of Sanofi China → General Manager of CStone Greater China

On April 1, CStone appointed Zhou You as the general manager of the company's Greater China region and the head of the company's commercial department.
He was fully responsible for the commercialization of the company's products and reported directly to Jiang Ningjun, the chairman and CEO of CStone
.

Before joining CStone, Zhou You served as Chief Marketing Officer of Sanofi Pasteur (China), responsible for vaccine-related business
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.